We look to invest in companies that are developing game changing medical technologies related to the diagnosis, monitoring or treatment of medical conditions or to improve standards of care.
Our investment interests include supporting companies in drug development from early stage platform technologies through to the more mature clinical stages. In addition, our focus also includes pharmaceutical technologies such as drug delivery and formulation.
We seek out innovative platforms that create value from waste materials, that reduce energy or resource consumption, and that lessen the environmental impact of energy and food production and transport. Our focus is on technology that displaces traditional industrial processes.
Proud to now be a PRI signatory
Xeraya is an official signatory to the UN-supported Principles for Responsible Investment (PRI) since March 2018, making a commitment to integrate environmental, social and governance (ESG) considerations into our investment decision-making process and policies.
We work with our investees to recognize and evaluate the impact of their operations on the environment, workers, communities and society as well as the potential impact of climate change on their activities. We aim towards contributing to the achievement of the UN Sustainable Development Goals.
Xeraya has developed extensive expertise in Shariah venture investments, leveraging our experience to broaden our Shariah-compliant portfolio through innovative structuring. We are supported by a distinguished advisory panel and external legal advisors.
Since our pioneering cross-border Shariah-compliant venture deal in 2014, Xeraya has expanded our compliant assets across various instruments including equity, debt, hybrids and warrants.
We’re a team of VC/PE who are excited about innovative ideas in life sciences. Submit your proposal to us!